Global Leading Market Research Publisher QYResearch announces the release of its latest report “Plant-based Empty Capsules – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Plant-based Empty Capsules market, including market size, share, demand, industry development status, and forecasts for the next few years.
For pharmaceutical formulation scientists, nutraceutical product developers, and oral delivery investors, the growing consumer demand for vegetarian, Halal, and Kosher-certified products has transformed capsule selection from a technical decision into a strategic imperative. Plant-based empty capsules are hollow capsules primarily made from plant-derived materials, commonly hydroxypropyl methylcellulose (HPMC) and other edible plant polysaccharides. Unlike traditional gelatin capsules, plant-based empty capsules contain no animal-derived ingredients, making them suitable for vegetarians and individuals with allergies to animal proteins. They offer excellent chemical stability and biocompatibility, providing a safe delivery vehicle for pharmaceuticals, dietary supplements, probiotics, enzymes, and other functional ingredients. Due to their natural and controllable composition, these capsules are widely used in pharmaceutical, nutraceutical, and functional food applications, particularly for oral dosage forms that require specific release sites and dissolution profiles. The global market for Plant-based Empty Capsules was estimated to be worth US$ 536 million in 2024 and is forecast to a readjusted size of US$ 817 million by 2031 with a CAGR of 6.1% during the forecast period 2025-2031. In 2024, the global sales volume reached 173.1 billion capsules, with an average price of US$ 31 per 10,000 capsules. This growth reflects a fundamental transformation in oral dosage form design: as consumers increasingly demand clean-label, ethically sourced products, and pharmaceutical companies seek excipients with broader compatibility and stability profiles, plant-based capsules have emerged as the preferred alternative to traditional gelatin.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/4946371/plant-based-empty-capsules
Market Definition: The Evolution of Oral Dosage Forms
Plant-based empty capsules represent a distinct category within the capsule dosage form market, characterized by their use of non-animal-derived materials for capsule shell construction. The predominant material is hydroxypropyl methylcellulose (HPMC), a semisynthetic polymer derived from plant cellulose that offers several advantages over gelatin: lower moisture content, broader compatibility with hygroscopic and reactive ingredients, and absence of animal-derived components. Additional plant-based materials, including pullulan (fermented from tapioca) and starch-based formulations, serve niche applications with specific requirements.
The market is segmented by capsule size into 00#, 0#, 1#, 2#, 3#, and Others. Size 0 and size 1 capsules represent the largest volume segments, serving the majority of pharmaceutical and nutraceutical applications where fill weights typically range from 200-500 mg. Size 00 capsules serve high-dose formulations requiring larger fill volumes, while sizes 2 and 3 are used for lower-dose applications and specialized pediatric or geriatric formulations.
By application, the market is segmented into Pharmaceuticals, Health Supplements, and Others. Health supplements currently account for the largest revenue share, driven by the rapid growth of the global nutraceutical market and consumer preferences for vegetarian, clean-label products. Pharmaceuticals represent the fastest-growing segment, as major drug manufacturers increasingly adopt plant-based capsules for new product launches and reformulation initiatives.
Industry Dynamics: Four Pillars Shaping Market Evolution
1. Consumer-Driven Demand for Plant-Based Products
The most significant demand driver originates from shifting consumer preferences toward vegetarian, vegan, and ethically sourced products. Unlike traditional gelatin capsules, plant-based empty capsules contain no animal-derived ingredients, making them suitable for vegetarians and individuals with allergies to animal proteins. According to industry research, the global vegetarian population exceeds 1.5 billion, with plant-based product adoption growing at 8-10% annually across North America, Europe, and Asia-Pacific markets.
A critical distinction exists between discrete manufacturing considerations in capsule production—where individual capsules are manufactured as discrete units with precise dimensions and wall thickness—versus process manufacturing approaches in formulation development, where capsule compatibility with active ingredients determines formulation feasibility. Plant-based capsules offer advantages in both dimensions: their manufacturing processes are well-established and scalable, while their chemical stability and low moisture content provide superior compatibility with sensitive ingredients.
A typical case study from 2025 illustrates this market dynamic. A leading global nutraceutical company transitioned its entire portfolio of 45 supplement products from gelatin to HPMC capsules, citing consumer demand for vegetarian options and improved stability for probiotic and enzyme-containing formulations. The transition required an 18-month reformulation effort but resulted in a 22% increase in market share within the vegetarian supplement segment and enabled Halal and Kosher certifications across the product line.
2. Pharmaceutical Adoption and Regulatory Acceptance
They offer excellent chemical stability and biocompatibility, providing a safe delivery vehicle for pharmaceuticals, dietary supplements, probiotics, enzymes, and other functional ingredients. Due to their natural and controllable composition, these capsules are widely used in pharmaceutical, nutraceutical, and functional food applications, particularly for oral dosage forms that require specific release sites and dissolution profiles.
Pharmaceutical adoption of plant-based capsules has accelerated as major pharmacopoeias have established monographs for HPMC capsules. The United States Pharmacopeia (USP) includes HPMC capsules as a recognized dosage form, and the European Pharmacopoeia (Ph. Eur.) has established standards for HPMC capsule shells. This regulatory acceptance has reduced barriers to pharmaceutical adoption, enabling drug manufacturers to leverage plant-based capsules for both new product launches and lifecycle management of existing products.
A notable development is the increasing use of plant-based capsules for moisture-sensitive and reactive drug substances. HPMC capsules typically contain 3-5% moisture, compared to 12-16% for gelatin capsules, significantly reducing the risk of degradation for hygroscopic compounds. This property has made plant-based capsules the preferred platform for moisture-sensitive formulations, including many biologic and small molecule drug candidates.
3. Probiotic and Microbiome Therapeutics Expansion
The rapid growth of the probiotics and microbiome therapeutics market has created substantial demand for plant-based delivery systems. Probiotic bacteria are inherently sensitive to moisture and temperature; HPMC capsules’ lower moisture content provides a more stable environment for probiotic viability compared to gelatin capsules.
A case study from 2024 illustrates this application. A leading probiotic manufacturer reformulated its flagship product from gelatin to HPMC capsules, citing improved stability and the ability to make vegetarian claims. The reformulation resulted in a 30% extension of shelf life for viable probiotic counts and enabled the company to expand distribution into markets with strict Halal certification requirements.
4. Regional Manufacturing Expansion and Supply Chain Dynamics
The plant-based empty capsule market exhibits significant geographic concentration in manufacturing capacity, with Asia-Pacific emerging as both the largest production hub and fastest-growing market. China accounts for a substantial share of global production, with manufacturers including Shandong Healsee Capsule, Anhui Huangshan Capsule, Hunan Er-Kang Pharmaceutical, Hebei Kangxin Plant Capsule, Zhejiang Yueshan Capsule, Zhejiang Tianlong Capsule, Zhejiang Xinchang Kangping Capsule, Jiangsu Kangyoujian Biotechnology, Guizhou Guang De Li Pharmaceuticals, SUZHOU CAPSUGEL, Chongqing Heng Sheng Pharmaceutical, Jiangsu Youli Capsule, and Jinan Gaohua Medicinal Capsule representing the domestic supply base.
A notable trend is the geographic diversification of manufacturing capacity. Major multinational capsule manufacturers, including Qualicaps, Lonza, ACG Associated Capsules, Suheung, and CapsCanada, have established or expanded production facilities in key regions to reduce supply chain risk and serve local markets with shorter lead times. This localization trend accelerated following supply chain disruptions in 2020-2022 and continues to shape manufacturing strategies.
Competitive Landscape: Global Leaders and Regional Specialists
The plant-based empty capsule market features a competitive landscape combining multinational capsule manufacturers with strong regional players. Qualicaps, Lonza, ACG Associated Capsules, Suheung, and CapsCanada represent the global leader segment, with established quality systems, extensive customer relationships across pharmaceutical and nutraceutical sectors, and advanced manufacturing technologies. Evonik Specialty Chemicals brings deep expertise in functional excipients and specialty capsule technologies. Sunil Healthcare maintains a strong position in Asian markets. The Chinese market features a robust domestic supply base with multiple manufacturers serving both domestic and export markets.
A critical competitive dynamic is the increasing emphasis on functional capsule technologies. Manufacturers are developing plant-based capsules with enhanced properties, including enteric coatings for targeted release, modified dissolution profiles for sustained release, and color-coded capsules for brand differentiation. These functional capabilities create competitive differentiation in the premium pharmaceutical and specialty nutraceutical segments.
Strategic Implications for Decision-Makers
For pharmaceutical formulation scientists, plant-based capsules offer a versatile platform for developing stable, consumer-friendly oral dosage forms. The combination of low moisture content, broad compatibility, and regulatory acceptance enables formulation of moisture-sensitive and reactive compounds while addressing consumer preferences for plant-based excipients.
For nutraceutical product developers, plant-based capsules provide a clean-label, vegetarian solution that aligns with consumer preferences. The ability to make plant-based, Halal, and Kosher claims creates competitive differentiation in the crowded supplement market.
For investors, the 6.1% CAGR forecast signals a stable, growing market with favorable characteristics. The combination of expanding nutraceutical markets, pharmaceutical adoption, and consumer preferences for plant-based products creates sustained demand. Companies with advanced manufacturing capabilities, established quality systems, and strong customer relationships are best positioned for growth.
Conclusion: A Market Defined by Clean-Label Innovation
The plant-based empty capsule market represents one of the most dynamic segments in the oral dosage form landscape. The projected expansion to US$ 817 million by 2031 reflects the convergence of multiple industry trends: consumer demand for vegetarian and clean-label products, pharmaceutical adoption of plant-based excipients, and the growth of probiotic and microbiome therapeutics. For pharmaceutical and nutraceutical companies seeking to develop differentiated oral dosage forms that meet both technical requirements and consumer preferences, plant-based capsules have emerged as the platform of choice.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
